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Abstract
Background: ADAM33, the first asthma candidate gene identified by positional cloning, may be associated with
childhood asthma, lung function decline and bronchial hyperresponsiveness. However, replication results have
been inconclusive in smaller previous study populations probably due to inconsistencies in asthma phenotypes or
yet unknown environmental influences. Thus, we tried to further elucidate the role of ADAM33 polymorphisms
(SNPs) in a genetic analysis of German case control and longitudinal populations.
Methods: Using MALDI-TOF, ten ADAM33 SNPs were genotyped in 1,872 children from the International Study
of Asthma and Allergy in Childhood (ISAAC II) in a case control setting and further 824 children from the
longitudinal cohort Multicentre Study of Allergy (MAS). In both populations the effects of single SNPs and
haplotypes were studied and a gene environment analysis with passive smoke exposure was performed using SAS/
Genetics.
Results: No single SNP showed a significant association with doctor's diagnosis of asthma. A trend for somewhat
more profound effects of ADAM33 SNPs was observed in individuals with asthma and BHR. Haplotype analyses
suggested a minor effect of the ADAM33 haplotype H4 on asthma (p = 0.033) but not on BHR. Associations with
non atopic asthma and baseline lung function were identified but no interaction with passive smoke exposure
could be detected.
Conclusion: The originally reported association between ADAM33 polymorphisms and asthma and BHR could
not be confirmed. However, our data may suggest a complex role of ADAM33 polymorphisms in asthma ethiology,
especially in non atopic asthma.
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Background
ADAM33, a disintegrin and metalloproteinase 33 has
been the first gene published, which had been identified
by positional cloning as a putative candidate gene for the
development of asthma and bronchial hyperresponsive-
ness [1]. It has been speculated that the ADAM33 gene,
expressed in airway smooth muscle cells and fibroblasts of
the lung, codes for a protein important for cell fusion, cell
adhesion, cell signalling and proteolysis. Furthermore,
ADAM33 was suggested to play a role in airway remode-
ling [2].
The ADAM33 gene is located on chromosome 20p13 and
37 SNPs have initially been identified [1]. Ever since the
first report of association between ADAM33  polymor-
phisms and asthma in two Caucasian populations from
the UK and the USA, a number of replication studies have
been published with very diverse results. Various associa-
tions between different asthma phenotypes as well as with
BHR and several different SNPs in the gene have been
reported [3-7]. One possible explanation for this diversity
in replication results could be the heterogeneity between
study populations or between the definitions of asthma in
different study populations. It can be hypothesized that
ADAM33, involved in remodeling, may be especially
important in some specific forms of asthma. Thus, it may
be more relevant in adult or non-atopic than in atopic
asthma. Furthermore, it may affect lung function more
than atopy status. Finally, environmental factors such as
passive smoke exposure could potentially interact with
ADAM33 in exerting its remodeling function in the lung
as ADAM33 also seems to be involved in COPD mediated
processes[8].
We tested the hypothesis that the ADAM33 gene is associ-
ated with atopic or non atopic asthma, lung function and
BHR in a large nested case control study of German chil-
dren (N = 1,872; comparing 624 asthmatics and/or BHR
positives and 1,248 non-asthmatic, BHR negative, non-
atopic controls) and a German multicentre family based
birth cohort study (MAS) (888 children with DNA availa-
ble, 96 asthmatics and 792 non-asthmatics). The effect of
ten SNPs spanning the ADAM33 gene as indicated in fig-
ure 1, previously showing associations with asthma phe-
notypes in some populations, and haplotypes of these
SNPs were analysed.
Position of the genotyped polymorphisms (SNPs) in the ADAM33 gene in respect to the 22 exons (blue) and untranslated  regions (red) of the gene Figure 1
Position of the genotyped polymorphisms (SNPs) in the ADAM33 gene in respect to the 22 exons (blue) and 
untranslated regions (red) of the gene. SNPs nomenclature according to the initial report by Van Eerdewegh et al. and 
alternatively according to the rs system in brackets.Respiratory Research 2006, 7:91 http://respiratory-research.com/content/7/1/91
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Methods
Description of the case control study population
Between 1995 and 1996, cross sectional studies were con-
ducted in Munich (ISAAC II), Dresden (ISAAC II) and
Leipzig to assess the prevalence of asthma and allergies in
schoolchildren age 9 to 11 years [9,10]. As the popula-
tions and phenotyping methods have been described in
detail before [9], only an overview of the methods pertain-
ing to this analysis is given here. Parental questionnaires
for self-completion were sent through the schools to the
families including the ISAAC core questions while slightly
different questionnaires were used for the Leipzig popula-
tion [9]. All children in the three cities whose parents
reported that a doctor diagnosed "asthma" at least once or
"asthmatic, spastic or obstructive bronchitis" more than
once were defined as having asthma.
In Dresden and Munich, children underwent skin prick
testing for six common aeroallergens (Dermatophagoides
pteronyssinus, D. farinae, Alternaria tenuis, cat dander, and
mixed grass and tree pollen) while in Leipzig D. pteronys-
sinus, grass, birch and hazel pollen, cat and dog dander
was examined [10]. A positive skin reaction was defined as
a wheal size ≥ 3 mm after subtraction of the negative con-
trol [9].
In the Munich and Dresden population, standard baseline
lung function was measured and bronchial reactivity was
assessed in a random 50% sub-sample of the study popu-
lation by inhalation of nebulized, hyperosmolar saline
(4.5%). Children with a drop in FEV1 of 15% or more
from baseline were classified as positive for bronchial
hyperresponsiveness [9]. In the Leipzig population, meas-
urements of airway challenges utilizing cold-air challenge
were performed according to a previously published pro-
tocol [10]. In this case BHR was defined as a fall in FEV1
of 9% corresponding to a value as large or larger than the
95th percentile of the reference population [11].
For this analysis, all children of German origin who had
both DNA and IgE data available and had a doctor's diag-
nosis of asthma and/or showed BHR (N = 624, Munich n
= 230, Dresden n = 263, Leipzig n = 131) were selected
from the total study population. These children were
matched at a 1:2 ratio with a random selection of healthy,
non asthmatic, non atopic children without a diagnosis of
BHR (Munich n = 460, Dresden n = 526, Leipzig n = 262)
in the analysis.
Multicentre Allergy Study cohort
The German Multicentre Allergy Study (MAS) cohort has
been described in detail elsewhere [12,13]. Initially, 1,314
children born in five German cities in the year 1990 were
followed up from birth to the age of 13 years. For 888 chil-
dren DNA was available and of these, only children of
German origin were included in this study (n = 824).
Yearly follow-up visits included standardized interviews,
questionnaires, and physical examinations. In the MAS
study, asthma, hay fever and atopic dermatitis at age 10
were defined using the ISAAC-core questions for children
as described for the ISAAC study population.
Serum samples were obtained from the children at birth,
and at 1, 2, 3, 5, 6, 7 and 10 years of age. Total IgE, specific
IgE antibodies to food allergens and inhalant allergens
(Dermatophagoides pteronyssinus, cat dander, mixed grass,
birch pollen, as well as dog dander from age 3 years on)
were determined by CAP-RAST FEIA (Pharmacia &
Upjohn, Freiburg, Germany). In the MAS study, atopy was
defined as a specific IgE level (CAP I) of ≥ 0.35 kU/l at age
7 or 10 years, respectively.
While pulmonary function tests were performed at age 7,
10 and 13, bronchial hyperresponsiveness was only
assessed at age 7 in 610 individuals [14]. Bronchial chal-
lenges in the MAS study were conducted after baseline
spirometry using increasing concentrations of histamine
(usually from 0.5 mg/ml to 8.0 mg/ml) according to
standard procedures. The 90th percentile of the distribu-
tion of PC20FEV1 in a healthy subsample corresponded to
0.85 mg/ml. Bronchial hyperresponsiveness was defined
as a PC20FEV1 greater than this value.
Current environmental smoke exposure was defined as
any current environmental tobacco smoke exposure at the
age of the survey in ISAAC (9–11) and at the age 10-survey
in MAS according to the information derived from paren-
tal questionnaires. In utero exposure to maternal smoking
was assessed by a positive answer to the question "Did the
mother of the child smoke during pregnancy?". Informed
written consent was obtained from all parents of children
included in the ISAAC and MAS studies. All study meth-
ods were approved by the local ethics committees.
Genotyping methods
For genotyping, the MassARRAY system (Sequenom, San
Diego, USA) was used as previously described in detail
[15]. All PCR reactions were performed using standard
thermocyclers (MJ Research, Waltham, USA). First, a PCR
was carried out. To remove excessive dNTPs, shrimp alka-
line phosphatase was added to the PCR products. The
base-specific extension reaction was performed in 10 µl
reactions by Thermosequenase (Amersham, Piscataway,
USA). For the base extension reaction the denaturation
was performed at 94°C for 2 min, followed by 94°C for 5
sec, 52°C for 5 sec, and 72°C for 10 sec for 55 cycles. The
final base extension products were treated with Spectro-
CLEAN resin to remove salts out of the reaction buffer,
and 16 µl of water was added into each base extension
reaction. After a quick centrifugation (2,000 rpm, 3 min)Respiratory Research 2006, 7:91 http://respiratory-research.com/content/7/1/91
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the reaction solution was dispensed onto a 384 format
SpectroCHIP pre-spotted with a matrix of 3-hydroxypico-
linic acid (3-HPA) by using a SpectroPoint nanodispenser.
A modified Bruker Biflex matrix assisted laser desorption
ionization-time-of-flight mass spectrometer was used for
data acquisitions from the SpectroCHIP. Genotyping calls
were made in real time with MASSARRAY RT software
(Sequenom, San Diego, USA).
Statistical analysis
Deviations from Hardy-Weinberg equilibrium were inves-
tigated for all polymorphisms using the χ2 statistic, with
expected frequencies derived from allele frequencies.
Associations between SNPs and qualitative outcomes
were determined using Cochran-Armitage-Trend-tests and
χ2-tests in dominant models of the rare allele. Differences
in lung function parameters were tested by univariate var-
iance analysis and t-tests in dominant or recessive models.
Linkage Disequilibrium (LD) and the LD block structure
were assessed using Haploview [16] and haplotype analy-
sis was performed for all tagging SNPs after haplotype fre-
quencies had been estimated by the EM (expectation-
maximisation) algorithm [17]. Haplotype associations
with asthma and BHR were calculated with the haplotype
procedure in SAS/Genetics. In addition, haplotype trend
regression models were estimated, where the estimated
probabilities of the haplotypes were modelled in a logistic
regression as independent variables [18].
For asthma as a binary outcome, logistic regression mod-
els for gene-environment interactions were used to esti-
mate the combined effect of each SNP with exposure to
environmental tobacco smoke (in utero and at time of
survey). A Botto Khoury approach summarizing the data
in a 2 × 4 table allowed for the evaluation of the inde-
pendent and combined roles of genotype and exposure on
disease risk [19].
All statistical analyses were carried out using the SAS sta-
tistical software package (Version 9.1) and the SAS/Genet-
ics module.
Results
Ten polymorphisms previously identified and showing
associations in at least one replication study were selected
for genotyping (table 1). These SNPs, located in the 3' half
of the gene, spanned the known ADAM33 linkage struc-
ture as indicated in figure 1. Call rates for SNPs in
ADAM33  ranged from 90.9% to 93.7% in the family
based study population, from 92.1% to 94.3% in the case
control population and from 91.9% to 94.0% in the
pooled sample as indicated in table 1. All SNPs were in
Hardy Weinberg equilibrium in both populations. In the
population based cross sectional study populations from
East and West Germany, all SNPs showed allele frequen-
cies similar to those previously published in other Cauca-
sian populations (table 1). Genotype frequencies and
linkage disequilibrium were almost identical in both the
case control population and the MAS cohort (data not
shown).
Single SNP analyses with qualitative traits
Associations between ADAM33 polymorphisms and the
phenotypes asthma and BHR were investigated in both
populations. As children in the case control sample were
9–11 years old at the time of disease status assessment and
children in the longitudinal MAS study population were
assessed using the same ISAAC core questions at age 10,
all analyses of association with asthma in the MAS popu-
lation were also performed at this and no other age. As
BHR values were only available at age 7 but not at age 10
in the MAS population, BHR was analyzed separately in
both populations.
No significant association could be detected between any
tested SNP and doctor's diagnosed asthma, neither in the
case control population nor in the cohort study, nor in the
pooled dataset (table 2). However, the risk to develop non
atopic asthma (as defined as a doctor's diagnosis of
asthma in the absence of a positive skin prick test) was
increased in carriers of the polymorphic A allele in S1 (OR
1.53, 95%CI 1.01–2.31, p = 0.042) and in carriers of the
polymorphic G allele in V4 (OR 1.44, 95%CI 1.03–2.01,
p = 0.031). Furthermore, the risk for non atopic asthma
was decreased in carriers of the polymorphic T allele for
M+1 (OR = 0.60, 95%C.I. 0.40 – 0.91, p = 0.016).
No significant association between ADAM33  polymor-
phisms and BHR, assessed by histamine challenge in the
MAS population at age 7 or with hypertonine saline inha-
lation or cold air challenge in the case control population
at age 9–11, was observed as shown in table 2. As the ini-
tial study by van Eerdewegh et al. [1] suggested the major
effect of ADAM33  polymorphisms in individuals with
asthma and concomitant BHR, we investigated this spe-
cific phenotype in the case control population. Again, no
SNP reached statistical significance in the association
analysis (table 2). As BHR values were only available at
age 7 but not at age 10 in the MAS cohort study and dif-
ferent procedures were used to define BHR in both study
populations, no combined analysis with both outcome
variables was performed.
Single SNP analyses with lung function measurements
Next, the effects of ADAM33 SNPs on baseline lung func-
tion measurements (FVC, FEV1, MEF25, MEF50 and
MEF75) were investigated in cases (asthma and/or BHR
positive) and controls separately (table 3). In cases, FVC
was increased in carriers of S2, T1 and T2 polymorphismsR
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Table 1: Description of the investigated ADAM33 SNPs and assay conditions in the case control and cohort study population.
position in original 
publication
rs numbers Alleles Minor Allele Frequency PCR Primer Extension Primer Callrate (%)
Case Control Cohort based
F+1 rs511898 G/A 0.38 0.36 fwd ACGTTGGATGAAAATACTGGGACTCGAGGC
rev ACGTTGGATGTGCTGTATCTATAGCCCTCC
ACTCGAGGCCTGTGAATTCC 93.73
M+1 rs3918395 G/T 0.15 0.13 fwd ACGTTGGATGGGGCACCAATTAACTAAGGC
rev ACGTTGGATGTGAGGGCATGGAAGGTTCAG
GCCGGCTCCCAAGCTCC 92.03
S1 rs3918396 G/A 0.09 0.09 fwd ACGTTGGATGAGTCGGTAGCAACACCAGGC
rev ACGTTGGATGAATCCCCGCAGACCATGACAC
CCTGCTGGCCATGCTCCTCAGC 92.99
S2 rs528557 G/C 0.28 0.28 fwd ACGTTGGATGAGTCGGTAGCAACACCAGG
rev ACGTTGGATGACCATGACACCTTCCTGCTG
GCTGCCTCTGCTCCCAGG 91.88
ST+4 rs44707 A/C 0.41 0.41 fwd ACGTTGGATGGGAGTGAAAAGATGTGCTGG
rev ACGTTGGATGCCACTTCCTCTGCACAAATC
ACAAATCACCTCTGTCACCC 92.58
ST+5 rs597980 C/T 0.44 0.45 fwd ACGTTGGATGAGAGAACTGGGTTAAGGCAG
rev ACGTTGGATGCCAGCACATCTTTTCACTCC
ACTCCATACCACTGGTCAGCTG 93.81
ST+7 rs574174 G/A 0.19 0.19 fwd ACGTTGGATGCTGCCCTTGATGATTCCAAG
rev ACGTTGGATGGGAACATCACAGGAAATGAC
ACTGTCCCCATCCCATC 93.66
T1 rs2280091 T/C 0.16 0.14 fwd ACGTTGGATGTTCCCTTCTCCCTTCCCTCTC
rev ACGTTGGATGTTGCTCAGCCCCAAAGATGG
GGGCGGCGTTCACCCCA 93.77
T2 rs2280090 C/T 0.16 0.14 fwd ACGTTGGATGTTCCCTTCTCCCTTCCCTCTC
rev ACGTTGGATGTTGCTCAGCCCCAAAGATGG
CCCCACAGCCACTGGACAG 93.95
V4 rs2787094 C/G 0.22 0.23 fwd ACGTTGGATGAGAAACAGGAAGGAAGGTCC
rev ACGTTGGATGTATGGTTCGACTGAGTCCAC
CTGAGTCCACACTCCCCTG 93.84Respiratory Research 2006, 7:91 http://respiratory-research.com/content/7/1/91
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while FEV1 was increased in carriers of S2 and M+1 poly-
morphisms. In contrast to polymorphism S1, the presence
of the polymorphic C allele in S2 increased the values for
MEF75. In controls, negative effects on MEF50 were
observed with ST+5 and MEF75 was increased in carriers
of the M+1 or S2 SNP.
Haplotype analysis
In a further step, haplotypes were estimated in both pop-
ulations for all samples genotyped successfully for at least
one ADAM33 SNP (1,802 in the case control population
and 782 in the MAS cohort) using the EM algorithm. The
estimated frequencies of all common ADAM33  haplo-
types built from the eight SNPs F+1, S1, S2, ST+4, ST+5,
ST+7, T1 and V4 and all ten SNPs are presented in table 4.
As SNPs M+1, T1 and T2 were in extremely tight linkage
disequilibrium, polymorphisms M+1 and T2 contributed
no additional information to the haplotype and thus were
excluded from the further haplotype building procedure.
One common haplotype, H4 (G-G-G-C-C-G-T-G),
showed a weak but not significant association with
asthma in the case control population but not in the
cohort as indicated in table 5a. This association became
significant in the pooled analysis. No association was
found with BHR (data not shown). When a haplotype
trend regression was performed for the haplotype H4, an
OR of 1.57 (95%CI 0.99–2.51, p = 0.057) in the pooled
population was observed.
Gene environment interaction analysis
As it was hypothesised that ADAM33 could influence the
effects of passive smoke exposure on asthma, BHR or lung
function, gene environment interactions were assessed
using a Botto Khoury approach. However, no such inter-
actions could be detected (data not shown).
Discussion
We have genotyped 2,696 subjects including more than
700 children with asthma and/or BHR for 10 SNPs in the
ADAM33 gene. For doctor's diagnosed asthma, no SNP
showed a significant association in any of the analyzed
populations. A trend for somewhat more profound but
not significant effects of ADAM33 SNPs was observed in
individuals with asthma and BHR, for which trait the
most significant association results were reported in the
original study on ADAM33. However, in the case control
population, these associations did just not reach statistical
significance. Haplotype analyses suggested a minor effect
of the ADAM33 haplotype H4 on asthma but not BHR. A
number of individual SNPs showed an association with
non atopic asthma in the case control population. A
diverse picture evolved when the effects of ADAM33 pol-
ymorphisms on baseline lung function were measured.
Table 2: Odds ratios (OR) and 95% confidence intervals (95% CI) for the association between single ADAM33 polymorphisms and 
asthma and BHR in the case-control population (age 9–11) and in the cohort study population assessed at age ten for asthma and age 
seven for BHR.
Asthma BHR1 Asthma and BHR2
SNP case-control study cohort study pooled case-control study cohort study case-control study
F+1 0.92 (0.72–1.17)
p = 0.502
0.94 (0.58–1.52)
p = 0.795
0.92 (0.74–1.15)
p = 0.478
1.27 (0.96–1.69)
p = 0.095
1.01 (0.63–1.61)
p = 0.962
1.61 (0.90–2.88)
p = 0.105
M+1 0.86 (0.65–1.13)
p = 0.269
0.94 (0.53–1.65)
p = 0.819
0.89 (0.70–1.14)
p = 0.351
1.18 (0.88–1.59)
p = 0.274
1.03 (0.61–1.74)
p = 0.919
1.46 (0.84–2.54)
p = 0.177
S1 1.23 (0.90–1.69)
p = 0.201
1.16 (0.64–2.10)
p = 0.635
1.20 (0.90–1.58)
p = 0.210
1.27 (0.90–1.81)
p = 0.175
1.19 (0.67–2.14)
p = 0.552
1.10 (0.54–2.25)
p = 0.789
S2 0.99 (0.78–1.26)
p = 0.949
0.97 (0.60–1.56)
p = 0.893
0.99 (0.80–1.22)
p = 0.908
1.29 (0.98–1.69)
p = 0.073
1.00 (0.63–1.59)
p = 0.989
1.72 (0.99–3.00)
p = 0.052
ST+4 1.04 (0.81–1.34)
p = 0.766
1.31 (0.79–2.18)
p = 0.292
1.10 (0.87–1.37)
p = 0.432
0.99 (0.74–1.32)
p = 0.956
1.08 (0.67–1.74)
p = 0.762
1.22 (0.69–2.18)
p = 0.490
ST+5 0.94 (0.73–1.22)
p = 0.649
0.80 (0.48–1.33)
p = 0.384
0.89 (0.71–1.12)
p = 0.338
0.95 (0.71–1.28)
p = 0.748
1.20 (0.71–2.00)
p = 0.495
0.91 (0.51–1.60)
p = 0.731
ST+7 1.11 (0.86–1.42)
p = 0.428
1.16 (0.71–1.89)
p = 0.549
1.10 (0.88–1.38)
p = 0.384
1.20 (0.90–1.59)
p = 0.209
1.15 (0.72–1.84)
p = 0.562
0.96 (0.55–1.70)
p = 0.901
T1 0.96 (0.74–1.25)
p = 0.762
0.92 (0.53–1.60)
p = 0.764
0.97 (0.76–1.23)
p = 0.804
1.20 (0.90–1.61)
p = 0.213
1.12 (0.67–1.88)
p = 0.662
1.50 (0.87–2.59)
p = 0.141
T2 0.95 (0.73–1.24)
p = 0.711
0.88 (0.50–1.55)
p = 0.666
0.96 (0.76–1.22)
p = 0.731
1.21 (0.91–1.62)
p = 0.196
1.14 (0.68–1.91)
p = 0.622
1.51 (0.88–2.61)
p = 0.134
V4 1.22 (0.95–1.55)
p = 0.115
0.82 (0.51–1.34)
p = 0.439
1.11 (0.90–1.38)
p = 0.329
1.13 (0.85–1.49)
p = 0.402
1.13 (0.71–1.78)
p = 0.608
1.31 (0.76–2.26)
p = 0.332
1No pooled analysis because of different techniques of BHR assessment in the case-control study and in the cohort study
2 No analysis in the cohort study because of low number of casesRespiratory Research 2006, 7:91 http://respiratory-research.com/content/7/1/91
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However, these associations did not remain significant
after correction for multiple testing. No interaction with
passive smoke exposure could be detected.
ADAM33  was the first published candidate gene for
asthma identified by positional cloning. In the initial
report 37 SNPs in the ADAM33 gene have been identified
and 15 polymorphisms have been genotyped in a UK and
a US study population [1]. Even within these two popula-
tions, different SNPs were associated with asthma and
BHR. Associations were significantly stronger in those
cases additionally showing BHR, suggesting that ADAM33
acts via lung specific mechanisms. A putatively functional
role for ADAM33 in the pathogenesis of asthma has been
hypothesised as ADAM33 is expressed in smooth muscle
cells of the bronchial and vascular system in the lung
[1,20]. It has been speculated that ADAM33 may act as a
protease activating cytokine or induce airway smooth
muscle proliferation. ADAM33 and its so far identified
polymorphisms may have less to do with atopic inflam-
mation and more with non atopic lung specific forms of
asthma. To a somewhat lesser degree, this initial BHR
effect was confirmed in our study population.
In terms of replication on a population level, the role of
ADAM33 SNPs in asthma remains controversial. It seems
that even the studies reporting a positive association
between ADAM33 SNPs and atopic phenotypes are inho-
mogeneous in their findings (table 6). These inconsisten-
cies in replication may have different reasons. They could
be due to population heterogeneity, as some studies may
suggest. Howard and co-workers genotyped 8 SNPs in 4
different ethnical populations (Dutch, white Americans,
Hispanics and African Americans) and found a wide vari-
ety of associations between the different ethnical groups
and various ADAM33 SNPs [4]. No single SNP was associ-
ated with asthma in all 4 groups and when corrected for
multiple testing, only one association remained signifi-
cant. In studies of asthmatics with a Hispanic background,
no association with ADAM33  SNPs was observed with
Table 3a: Lung function parameters in the case-control study for all cases *)
SNP N1) MEF25 (%) Mean ± SD MEF50 (%) Mean ± SD MEF75 (%) Mean ± SD FEV1 (%) Mean ± SD FVC (%) Mean ± SD
F+1 wild type 165 89.82 ± 29.66 89.47 ± 22.54 91.90 ± 16.28 97.65 ± 11.44 97.64 ± 11.03
heterozygous 232 91.86 ± 32.06 91.22 ± 22.23 94.48 ± 18.53 99.32 ± 10.57 99.80 ± 10.02
homozygous 64 92.61 ± 23.45 90.28 ± 17.19 97.32 ± 18.00 98.56 ± 10.75 98.16 ± 10.75
M+1 wild type 317 90.75 ± 30.97 89.70 ± 22.29 93.19 ± 17.82 98.17 ± 11.43*r 98.12 ± 11.05
heterozygous 128 91.28 ± 28.43 91.51 ± 22.15 95.56 ± 17.50 99.01 ± 9.86 99.86 ± 9.83
homozygous 4 109.34 ± 23.03 98.95 ± 12.38 95.75 ± 23.07 109.31 ± 9.13 105.89 ± 9.71
S1 wild type 359 90.57 ± 30.08 90.00 ± 21.74 93.23 ± 17.00*v 98.29 ± 10.86 98.46 ± 10.72
heterozygous 86 94.29 ± 31.08 92.01 ± 24.43 97.23 ± 21.03 99.63 ± 11.23 99.58 ± 10.02
homozygous 4 73.47 ± 16.07 76.17 ± 10.97 78.46 ± 11.72 90.84 ± 5.11 96.06 ± 1.40
S2 wild type 215 91.22 ± 31.50 89.69 ± 22.15 92.14 ± 17.03*d 97.50 ± 11.49*d 96.97 ± 11.32*v*d
heterozygous 202 91.30 ± 29.78 91.43 ± 22.16 96.12 ± 18.27 99.76 ± 10.73 100.55 ± 9.99
homozygous 31 95.31 ± 21.52 90.93 ± 22.04 94.54 ± 20.57 99.55 ± 9.27 98.70 ± 9.25
ST+4 wild type 158 90.05 ± 29.28 89.70 ± 22.41 93.18 ± 18.52 98.08 ± 10.38 99.09 ± 10.01
heterozygous 223 92.00 ± 29.50 91.32 ± 22.23 94.83 ± 18.14 99.06 ± 11.75 98.61 ± 11.11
homozygous 65 92.97 ± 34.91 90.22 ± 22.04 93.93 ± 14.12 98.68 ± 10.03 98.59 ± 11.39
ST+5 wild type 136 92.47 ± 31.51 91.10 ± 20.52 94.37 ± 15.25 99.26 ± 10.00 99.38 ± 10.88
heterozygous 236 91.87 ± 29.26 91.02 ± 23.37 94.65 ± 19.04 98.79 ± 11.61 98.62 ± 10.58
homozygous 88 87.50 ± 29.64 87.41 ± 20.55 91.39 ± 17.77 97.13 ± 10.41 98.48 ± 10.15
ST+7 wild type 285 90.28 ± 29.48 90.36 ± 21.92 93.30 ± 16.83 98.67 ± 10.93 99.10 ± 10.49
heterozygous 158 94.26 ± 31.56 91.07 ± 22.55 94.99 ± 19.60 98.98 ± 11.11 98.63 ± 10.92
homozygous 16 82.30 ± 24.76 82.94 ± 17.26 95.38 ± 16.31 93.87 ± 9.08 95.04 ± 7.62
T1 wild type 315 90.42 ± 31.04 89.55 ± 22.40 93.32 ± 17.78 98.07 ± 11.38 98.12 ± 10.83*d
heterozygous 135 92.59 ± 28.08 92.22 ± 21.39 95.50 ± 17.87 99.42 ± 9.78 100.10 ± 9.98
homozygous 8 98.09 ± 27.48 90.95 ± 23.47 91.61 ± 19.64 103.91 ± 11.37 103.30 ± 8.53
T2 wild type 317 90.60 ± 31.04 89.61 ± 22.34 93.37 ± 17.71 98.13 ± 11.36 98.14 ± 10.80*d
heterozygous 135 92.59 ± 28.08 92.22 ± 21.39 95.50 ± 17.87 99.42 ± 9.78 100.10 ± 9.98
homozygous 8 98.09 ± 27.48 90.95 ± 23.47 91.61 ± 19.64 103.91 ± 11.37 103.30 ± 8.53
V4 wild type 267 91.58 ± 30.15 89.98 ± 21.82 93.12 ± 17.14 98.24 ± 11.04 98.22 ± 10.82
heterozygous 163 89.70 ± 30.05 89.71 ± 22.19 94.63 ± 18.60 98.57 ± 10.65 99.20 ± 10.23
homozygous 26 95.52 ± 30.38 97.28 ± 24.60 96.90 ± 19.51 101.03 ± 11.93 99.82 ± 10.29
*) significant differences (p < 0.05) in lung function parameters between genotypes are printed in bold letters,
*v denotes significant differences in variance analysis,
*d denotes significant differences in t-test for a dominant model,
*r significant differences in t-test for a recessive model
1)N refers to the first lung function parameter. Minimal deviations of N in the other lung function parameters are possible.Respiratory Research 2006, 7:91 http://respiratory-research.com/content/7/1/91
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asthma [21]. Thus, differences in haplotype structure or
even in the occurrence of SNPs may exist between ethnic-
ities, which have not yet been investigated sufficiently for
ADAM33 but which are known to exist for a number of
other genes.
A further explanation for the differences in replication
results might be that the definition of asthma may have
varied between studies. As ADAM33 may specifically
affect remodeling of the lungs, the impact of genetic vari-
ations in ADAM33 could be variable in different forms of
asthma. In other words, ADAM33 genetics may have more
impact on those forms of asthma which are less driven by
atopy and more associated with lung specific mecha-
nisms. Our data indeed suggests that the known ADAM33
SNPs have only a minor impact on the most common
form of childhood asthma, which is highly correlated
with atopy in most study populations. In contrast, a
number of ADAM33  SNPs were associated with non
atopic asthma as well as baseline lung function measure-
ments in our study. However, the pattern of association
remains complex as different SNPs are associated with
non atopic asthma and determinants of lung function.
Moreover, ADAM33 SNPs also seem to play a different
role in adult asthma than in childhood asthma as indi-
cated by previously published studies. Werner et al. geno-
typed 15 ADAM33 SNPs in a family based and in an adult
case control population and observed variable associa-
tions between SNPs and asthma within the two popula-
tions and also in respect to the initially reported
associations [7]. Very large studies investigating child-
hood asthma by Lind [21] and Raby [6] could not find
any association between single ADAM33 SNPs or haplo-
types and childhood asthma. However, no analyses of
ADAM33  effects on non atopic asthma have been
reported in these studies of childhood asthma. While
Raby et al. [6] stated that it seems very unlikely that these
negative studies were underpowered to detect an associa-
tion, a recent meta analysis suggested, that the odds ratio
for the ADAM33 locus may be in the order of 1.4 or lower
Table 3b: Lung function parameters in the case-control study for all controls *)
SNP N1) MEF25 (%) Mean ± SD MEF50 (%) Mean ± SD MEF75 (%) Mean ± SD FEV1 (%) Mean ± SD FVC (%) Mean ± SD
F+1 wild type 291 98.48 ± 25.83 97.93 ± 19.80 99.22 ± 17.82 100.59 ± 9.86 98.28 ± 10.49
heterozygous 348 101.46 ± 30.46 99.08 ± 21.41 100.69 ± 17.83 101.76 ± 10.29 99.08 ± 10.26
homozygous 111 99.44 ± 29.96 99.63 ± 20.23 101.52 ± 19.80 101.38 ± 10.75 98.47 ± 10.38
M+1 wild type 522 99.25 ± 27.06 98.22 ± 20.12 99.46 ± 17.92*d 101.06 ± 10.11 98.46 ± 10.51
heterozygous 201 101.97 ± 32.25 100.01 ± 21.94 102.51 ± 18.60 102.10 ± 10.69 99.39 ± 10.29
homozygous 12 95.45 ± 35.80 104.74 ± 19.55 104.98 ± 13.31 98.63 ± 8.56 96.65 ± 8.30
S1 wild type 627 100.12 ± 29.00 99.05 ± 20.58 100.58 ± 17.89 101.18 ± 10.28 98.67 ± 10.52
heterozygous 116 98.23 ± 27.90 97.01 ± 21.40 99.16 ± 19.84 101.78 ± 10.41 99.29 ± 10.11
homozygous 6 95.19 ± 21.20 98.62 ± 16.03 103.61 ± 13.45 103.74 ± 10.25 100.29 ± 11.22
S2 wild type 381 99.51 ± 26.91 98.44 ± 20.04 98.82 ± 17.78*d 100.94 ± 10.08 98.34 ± 10.67
heterozygous 292 101.59 ± 31.92 99.11 ± 22.33 101.88 ± 18.68 102.09 ± 10.56 99.55 ± 10.28
homozygous 62 97.76 ± 25.55 100.37 ± 16.24 101.35 ± 16.99 102.51 ± 9.76 98.97 ± 9.91
ST+4 wild type 257 100.02 ± 28.64 98.04 ± 20.98 100.06 ± 17.63 101.58 ± 9.86 99.20 ± 9.75
heterozygous 365 100.09 ± 28.74 99.28 ± 21.10 101.17 ± 19.05 101.39 ± 10.50 98.55 ± 10.50
homozygous 114 98.52 ± 28.40 98.83 ± 18.79 98.41 ± 16.62 100.07 ± 10.09 98.18 ± 11.43
ST+5 wild type 222 100.79 ± 31.48 101.33 ± 20.02*d 101.79 ± 17.87 101.33 ± 10.00 98.98 ± 10.29
heterozygous 380 99.54 ± 28.10 97.52 ± 21.27 99.77 ± 18.20 100.85 ± 10.58 98.12 ± 10.82
homozygous 148 99.48 ± 25.81 97.72 ± 19.54 99.23 ± 18.08 102.19 ± 9.46 99.74 ± 9.19
ST+7 wild type 507 100.34 ± 28.71 99.01 ± 20.67 100.26 ± 17.65 101.40 ± 10.17 98.93 ± 10.29
heterozygous 213 98.76 ± 29.25 98.00 ± 20.58 100.11 ± 19.04 100.65 ± 9.99 98.01 ± 10.35
homozygous 32 101.56 ± 24.74 98.45 ± 20.33 99.70 ± 19.21 103.37 ± 12.14 100.57 ± 12.16
T1 wild type 531 99.34 ± 27.07 98.23 ± 20.15 99.49 ± 18.08 101.07 ± 10.13 98.58 ± 10.53
heterozygous 205 101.94 ± 32.34 99.58 ± 21.96 101.97 ± 18.39 101.81 ± 10.47 99.12 ± 10.14
homozygous 15 95.29 ± 31.85 103.19 ± 18.07 101.58 ± 14.14 101.17 ± 9.28 98.59 ± 8.47
T2 wild type 532 99.31 ± 27.05 98.23 ± 20.13 99.51 ± 18.07 101.07 ± 10.12 98.57 ± 10.52
heterozygous 204 102.01 ± 32.41 99.58 ± 22.01 101.92 ± 18.42 101.80 ± 10.49 99.09 ± 10.16
homozygous 15 95.29 ± 31.85 103.19 ± 18.07 101.58 ± 14.14 101.17 ± 9.28 98.59 ± 8.47
V4 wild type 474 100.07 ± 28.66 98.91 ± 21.18 100.74 ± 18.35 101.32 ± 10.45 98.76 ± 10.49
heterozygous 249 99.87 ± 29.37 98.91 ± 19.75 99.86 ± 17.75 101.62 ± 9.80 99.16 ± 10.07
homozygous 35 99.31 ± 25.64 96.87 ± 19.30 100.16 ± 19.15 100.29 ± 11.81 96.95 ± 12.34
*) significant differences in lung function parameters between genotypes are printed in bold letters,
*v denotes significant differences in variance analysis,
*d denotes significant differences in t-test for a dominant model,
*r significant differences in t-test for a recessive model
1)N refers to the first lung function parameter. Minimal deviations of N in the other lung function parameters are possible.Respiratory Research 2006, 7:91 http://respiratory-research.com/content/7/1/91
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for SNPs known to date [3]. Even with large data sets such
as used in this study, the ability to detect risks of this mag-
nitude may be limited. Furthermore, it may be possible
that the known SNPs in ADAM33 are only a proxy for
additional, yet unidentified SNPs in the ADAM33 gene,
which could be the true cause for the observed but mixed
signals from this locus.
Finally, differences in the study populations in terms of
gene by environment interactions may also explain some
of the observed discrepancy in replication as has been sug-
gested to be the case with other genes inconsistently repli-
cated [22,23]. However, it is not clear, which
environmental factors may interact with ADAM33 genet-
ics and if these factors could influence the associations
between ADAM33 polymorphisms and asthma. As indi-
cated by our analysis, passive smoke exposure does not
seem to be one of these factors.
In the meantime, a total of five genes (ADAM33[1],
PHF11[24], DPP10 [25]GPRA [26] and HLA-G [27] have
been proposed as potential asthma genes by positional
cloning and some more may follow. What can we learn
from the experience with ADAM33? First, it seems that
genes identified by positional cloning have the same lim-
itations as other putative candidate genes suggested by
expression studies, or selected because of their biological
context in disease pathways. Positional cloning does not
prove but suggest a role of the gene in question for a spe-
cific disease. Further evidence however can only be
Table 5: Estimated haplotype frequencies and associations with asthma in case control and cohort populations
Haplotype Study 
population1)
Haplotype frequencies 
in the cases
Haplotype frequencies 
in the controls
Odds Ratio and 
Confidence intervals2)
p-value of 
χ2-Test
H1 G-G-G-A-T-G-T-C all 30.35% 32.21% 0.92(0.78–1.08) 0.293
ccs 30.90% 31.56% 0.97(0.81–1.15) 0.735
coh 30.03% 34.02% 0.83(0.58–1.19) 0.317
H2 G-G-G-C-C-G-T-C all 17.02% 16.69% 1.02(0.84–1.25) 0.804
ccs 16.77% 16.85% 0.99(0.80–1.24) 0.939
coh 16.93% 16.32% 1.04(0.67–1.63) 0.847
H3 A-G-C-A-C-G-C-C all 12.98% 14.08% 0.91(0.73–1.13) 0.402
ccs 13.60% 14.85% 0.90(0.71–1.15) 0.406
coh 10.33% 12.04% 0.84(0.49–1.45) 0.531
H4 G-G-G-C-C-G-T-G all 12.96% 10.44% 1.28(1.02–1.60) 0.033
ccs 13.15% 10.65% 1.27(0.99–1.64) 0.063
coh 11.43% 9.85% 1.18(0.70–2.00) 0.528
H5 A-A-C-A-T-A-T-G all 8.35% 7.69% 1.09(0.83–1.43) 0.517
ccs 8.62% 7.16% 1.22(0.90–1.66) 0.191
coh 7.18% 9.07% 0.78(0.41–1.46) 0.430
H6 A-G-G-C-C-A-T-C all 6.70% 6.54% 1.03(0.76–1.38) 0.867
ccs 6.17% 6.67% 0.92(0.65–1.30) 0.638
coh 8.99% 6.19% 1.50(0.82–2.72) 0.184
1) All = case control study and cohort study population pooled, ccs = case control study (n = 358 cases/n = 1198 controls), coh = cohort study (n 
= 82 cases/n = 464 controls); children without haplotype information were excluded
2) Odds Ratios were calculated as one haplotype vs. all others
Table 4: Estimated frequencies of common haplotypes in different German populations
Estimated frequencies in the different populations3
F+1 M+12 S1 S2 ST4 ST+5 ST+7 T1 T22 V4 pooled case-control study cohort study
H1 G G GG A T G T C C 31.59% (31.62%) 31.42% (31.43%) 32.21% (32.24%)
H2 G G GG C C G T C C 16.63% (16.66%) 16.66% (16.67%) 16.54% (16.62%)
H3 A T GC A C G C T C 14.00% (13.91%) 14.67% (14.67%) 12.50% (12.20%)
H4 G G GG C C G T C G 11.22% (11.20%) 11.02% (11.01%) 11.48% (11.48%)
H5 A G AC A T A T C G 7.84% (7.84%) 7.73% (7.73%) 8.12% (8.12%)
H6 A G GG C C A T C C 6.48% (6.50%) 6.68% (6.70%) 6.06% (6.07%)
Rare1 12.24% (12.28%) 11.82% (11.80%) 13.10% (13.27%)
1) Rare are all haplotypes with an estimated frequency < 0.03 in the pooled sample
2) SNPs which are excluded after choosing only tagging SNPs
3) Estimated frequencies of the 8-SNP-haplotype, in brackets estimated frequencies of the 10-SNP-haplotypeR
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Table 6: Comparison of previously reported association results1 with ADAM33 polymorphisms
Study Study population N2 ADAM33 SNPs and reported associations
cc = case control
fa = family study
cases/controls 
families (ind.)
F+1 I1 L-1 M+1 Q-1 S1 S2 ST+1 ST+4 ST+5 ST+7 T1 T2 T+1 V-1 V1 V4
Van Eerdewegh et al. US/UK combined (cc) 130/217 neg neg neg neg A A neg neg A neg A neg neg neg A neg A
UK (cc) (not reported) A neg neg neg A A A neg A neg neg neg neg neg A neg A
US (cc) (not reported) neg A A A neg neg neg neg neg neg neg A A A neg neg neg
US/UK (fa) 460fa (1840) A B neg neg neg
Lind et al. Mexican (cc) 190/160 neg neg neg neg neg neg
Puerto Rican (cc) 183/165 neg neg neg neg neg neg
Mexican/P. Rican (fa) 583fa (1749)3 neg neg neg neg neg neg
Raby et al.4 Non-Hispanic white (fa) 474 (1462) neg neg neg neg neg neg neg neg neg
Hispanic (fa) 47 (149) neg neg neg neg A neg A neg neg
African American (fa) 66 (203) neg neg neg neg neg neg neg neg neg
Werner et al. German (cc) 48/499 neg neg neg neg neg neg neg neg B A neg neg neg neg neg
German (fa) 171fa (732) A, B, AB neg neg neg neg B, AB neg A A neg neg neg neg neg neg
Howard et. al. African American (cc) 161/2655 neg A AT neg neg neg neg AT
US White (cc) 220/2295 neg A6, AT neg A A, AT A, AT neg neg
US Hispanic (cc) 113/1275 neg A AT neg A6, AT A, AT AT neg
Dutch White (cc) 180/1335 AT AT neg A, AT neg neg AT A
Blakey et al. Icelandic (cc) 348/262 neg neg neg neg neg neg neg neg neg neg neg neg neg
Nottingham (fa) 60fa (240) neg neg neg neg neg neg neg neg neg neg neg neg neg
1 association with asthma (= A), BHR (= B), Asthma and BHR (= AB) or Atopy (= AT) in different studies; SNPs which are not significantly associated = neg
2 in case-control studies number of cases and controls, in family studies number of families and individuals
3265 Mexican families and 318 Puerto Rican families, no association neither in single nor in pooled population
4in the study of Raby et al. 8 additional SNPs were investigated: G1, I1, KL+3, N1, S+1, T+2, V-2, V3. None of the additional SNPs showed an association with asthma.
5N is reported as maximum number of successfully genotyped subjects
6only a trend (0.05 < p ≤ 0.06)Respiratory Research 2006, 7:91 http://respiratory-research.com/content/7/1/91
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achieved by independent replication studies and func-
tional molecular genetics, which both may be tedious.
This process may take some time and the level of evidence
for or against the involvement of a certain gene in a com-
plex disease may only increase with time. Large and well
defined replications are needed and negative results ought
to be published.
Conclusion
Our data suggest that previously reported ADAM33 poly-
morphisms may only have a minor impact on the devel-
opment of asthma in German children.
Abbreviations
ADAM33 a disintegrin and metalloprotease 33
BHR bronchial hyperresponsiveness
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LD linkage disequilibrium
MAS Multicentre Allergy Study
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